MedTrace Logo

MD Ezetimibe Cyclosporine Interaction (0653-057)

NCT00653276 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-08-15

No results posted yet for this study

Summary

Study to determine the effect of multiple oral doses of ezetimibe on the pharmacokinetics of a single oral dose cyclosporine in young healthy males and females.

Conditions

  • Cholesterol

Interventions

DRUG

ezetimibe

ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.

DRUG

Comparator: cyclosporine

single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2004-01-31
Completion
2004-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00653276 on ClinicalTrials.gov